Factors associated with hepatitis C treatment uptake among females of childbearing age in New South Wales, Australia: A population-based study.
childbirth
direct acting antiviral therapy
drug dependence
female
hepatitis C virus
Journal
Drug and alcohol review
ISSN: 1465-3362
Titre abrégé: Drug Alcohol Rev
Pays: Australia
ID NLM: 9015440
Informations de publication
Date de publication:
30 May 2023
30 May 2023
Historique:
revised:
15
03
2023
received:
03
11
2022
accepted:
09
05
2023
pubmed:
31
5
2023
medline:
31
5
2023
entrez:
31
5
2023
Statut:
aheadofprint
Résumé
Females of childbearing age with hepatitis C virus (HCV) face increased marginalisation with intersecting, sex-specific barriers to direct acting antiviral (DAA) therapy. We assessed the factors associated with uptake of DAA therapy among females of childbearing age, including those with evidence of recent drug dependence. HCV notifications in New South Wales, Australia (1995-2017) were linked to opioid agonist therapy (OAT), hospitalisations, incarcerations, perinatal, HIV notifications, deaths and prescription databases. Recent drug dependence was defined as hospitalisation due to injectable drugs or receipt of OAT occurring in the DAA era (2016-2018). Logistic regression was used to analyse factors associated with DAA uptake among females of childbearing age (18-44), including those with recent drug dependence. Among 57,467 people with evidence of chronic HCV in the DAA era (2016-2018), 20,161 (35%) were female, including 33% (n = 6563/20,161) of childbearing age (18-44). Among all females of childbearing age (n = 6563) and those with evidence of recent drug dependence (n = 2278/6563, 35%), DAA uptake was lower among those who had given birth in the DAA era (vs. no birth record, all females of childbearing age; aOR: 0.74, 95% CI 0.61, 0.89; those with recent drug dependence; aOR 0.69, 95% CI 0.51, 0.93) and Aboriginal and Torres Strait Islander peoples (all females of childbearing age; aOR 0.81, 95% CI 0.71, 0.93; those with recent drug dependence aOR 0.75, 95% CI 0.62, 0.90). Females of childbearing age should be considered a key population for DAA therapy. Enhancing antenatal and postnatal HCV care may be critical in the pursuit towards elimination.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Cancer Council NSW
ID : RG17-06
Organisme : New South Wales Ministry of Health, Bloodborne viruses and sexually transmissible infections research, strategic interventions, and evaluation (BRISE)
Informations de copyright
© 2023 Australasian Professional Society on Alcohol and other Drugs.
Références
Degenhardt L, Peacock A, Colledge S, Leung J, Grebely J, Vickerman P, et al. Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review. Lancet Glob Health. 2017;5:e1192-e207.
Esmaeili A, Mirzazadeh A, Carter GM, Esmaeili A, Hajarizadeh B, Sacks HS, et al. Higher incidence of HCV in females compared to males who inject drugs: a systematic review and meta-analysis. J Viral Hepat. 2017;24:117-27.
Tracy D, Hahn JA, Lewis CF, Evans J, Briceño A, Morris MD, et al. Higher risk of incident hepatitis C virus among young women who inject drugs compared with young men in association with sexual relationships: a prospective analysis from the UFO study cohort. BMJ Open. 2014;4:e004988.
Australian Government Department of Health. Fifth National Hepatitis C Strategy, 2018-2022. 2018.
Shirley-Beavan S, Roig A, Burke-Shyne N, Daniels C, Csak R. Women and barriers to harm reduction services: a literature review and initial findings from a qualitative study in Barcelona, Spain. Harm Reduct J. 2020;17:78.
Pinkham S, Stoicescu C, Myers B. Developing effective health interventions for women who inject drugs: key areas and recommendations for program development and policy. Adv Prev Med. 2012;2012:269123.
Iversen J, Page K, Madden A, Maher L. HIV, HCV and health-related harms among women who inject drugs: implications for prevention and treatment. J Acquir Immune Defic Syndr. 2015;69(Suppl 2):S176-81.
Harris M, Rhodes T. Hepatitis C treatment access and uptake for people who inject drugs: a review mapping the role of social factors. Harm Reduct J. 2013;10:7.
Wolfson L, Schmidt RA, Stinson J, Poole N. Examining barriers to harm reduction and child welfare services for pregnant women and mothers who use substances using a stigma action framework. Health Soc Care Community. 2021;29:589-601.
Dugan E, Blach S, Biondi M, Cai Z, DePaola M, Estes C, et al. Global prevalence of hepatitis C virus in women of childbearing age in 2019: a modelling study. Lancet Gastroenterol Hepatol. 2021;6:169-84.
Ko JY, Haight SC, Schillie SF, Bohm MK, Dietz PM. National trends in hepatitis C infection by opioid use disorder status among pregnant women at delivery hospitalization-United States, 2000-2015. MMWR Morb Mortal Wkly Rep. 2019;68:833-8.
Patrick SW, Bauer AM, Warren MD, Jones TF, Wester C. Hepatitis C virus infection among women giving birth-Tennessee and United States, 2009-2014. MMWR Morb Mortal Wkly Rep. 2017;66:470-3.
Schillie SF, Canary L, Koneru A, Nelson NP, Tanico W, Kaufman HW, et al. Hepatitis C virus in women of childbearing age, pregnant women, and children. Am J Prev Med. 2018;55:633-41.
Tajiri H, Miyoshi Y, Funada S, Etani Y, Abe J, Onodera T, et al. Prospective study of mother-to-infant transmission of hepatitis C virus. Pediatr Infect Dis J. 2001;20:10-4.
Yeung LT, King SM, Roberts EA. Mother-to-infant transmission of hepatitis C virus. Hepatology. 2001;34:223-9.
Dienstag JL. Sexual and perinatal transmission of hepatitis C. Hepatology. 1997;26:66S-70S.
European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C 2018. J Hepatol. 2018;69:461-511.
Rojas TR, Di Beo V, Delorme J, Barre T, Mathurin P, Protopopescu C, et al. Lower HCV treatment uptake in women who have received opioid agonist therapy before and during the DAA era: the ANRS FANTASIO project. Int J Drug Policy. 2019;72:61-8.
Valerio H, Alavi M, Law M, Tillakeratne S, Amin J, Janjua NZ, et al. High hepatitis C treatment uptake among people with recent drug dependence in New South Wales, Australia. J Hepatol. 2021;74:293-302.
Valerio H, Alavi M, Silk D, Treloar C, Martinello M, Milat A, et al. Progress towards elimination of hepatitis C infection among people who inject drugs in Australia: the ETHOS engage study. Clin Infect Dis. 2021;73:e69-78.
Kanwal F, Kramer JR, El-Serag HB, Frayne S, Clark J, Cao Y, et al. Race and gender differences in the use of direct acting antiviral agents for hepatitis C virus. Clin Infect Dis. 2016;63:291-9.
Bartlett SR, Yu A, Chapinal N, Rossi C, Butt Z, Wong S, et al. The population level care cascade for hepatitis C in British Columbia, Canada as of 2018: impact of direct acting antivirals. Liver Int. 2019;39:2261-72.
Larney S, Madden A, Marshall AD, Martin NK, Treloar C. A gender lens is needed in hepatitis C elimination research. Int J Drug Policy. 2022;103:103654.
Australian institute of health and welfare. Australia's Mothers and Babies, 2022. Available from: https://www.aihw.gov.au/reports/mothers-babies/australias-mothers-babies-data-visualisations/contents/summary
Janjua NZ, Islam N, Kuo M, Yu A, Wong S, Butt ZA, et al. Identifying injection drug use and estimating population size of people who inject drugs using healthcare administrative datasets. Int J Drug Policy. 2018;55:31-9.
Alavi M, Law MG, Valerio H, Grebely J, Amin J, Hajarizadeh B, et al. Declining hepatitis C virus-related liver disease burden in the direct-acting antiviral therapy era in New South Wales, Australia. J Hepatol. 2019;71:281-8.
Australian Institute of Health and Welfare. Australia's mothers and babies, web report. 15 December 2021. Available from: https://www.aihw.gov.au/reports/mothers-babies/australias-mothers-babies-data-visualisations/contents/labour-and-birth/place-of-birth. Accessed 12 April 2022
Pearce ME, Bartlett SR, Yu A, Lamb J, Reitz C, Wong S, et al. Women in the 2019 hepatitis C cascade of care: findings from the British Columbia Hepatitis Testers cohort study. BMC Womens Health. 2021;21:330.
Department of Health. Clinical practice guidelines: pregnancy care. Canberra: Australian Government Department of Health; 2018 Available from: https://www.health.gov.au/sites/default/files/pregnancy-care-guidelines_0.pdf
Jhaveri R, Yee LM, Antala S, Murphy M, Grobman WA, Shah SK. Responsible inclusion of pregnant individuals in eradicating HCV. Hepatology. 2021;74:1645-51.
Kushner T, Cohen J, Tien PC, Terrault NA. Evaluating women's preferences for hepatitis C treatment during pregnancy. Hepatol Commun. 2018;2:1306-10.
Chappell CA, Scarsi KK, Kirby BJ, Suri V, Gaggar A, Bogen DL, et al. Ledipasvir plus sofosbuvir in pregnant women with hepatitis C virus infection: a phase 1 pharmacokinetic study. Lancet Microbe. 2020;1:e200-e8.
El-Sayed MH, Elakel W, Elsharkawy A, et al. DAA therapy in women of child bearing age: accidental conception during therapy and pregnancy outcome. Vienna, Austria; 4 11: The International Liver Congress 2019; 2019 (abstr THU-137).
Gartner K, Elliott K, Smith M, Pearson H, Hunt G, Martin RE. “People in regular society don't think you can be a good mother and have a substance use problem”: participatory action research with women with substance use in pregnancy. Can Fam Physician. 2018;64:e309-e16.
Jones A, Schneider K, Falade-Nwulia O, Sterner G, Tobin K, Latkin C. Social networks, stigma, and hepatitis C care among women who inject drugs: findings from a community recruited sample. J Psychoactive Drugs. 2022 [Epub ahead of print].
Earnshaw VA, Watson RJ, Eaton LA, Brousseau NM, Laurenceau J-P, Fox AB. Integrating time into stigma and health research. Nat Rev Psychol. 2022;1:236-47.
Westreich D, Greenland S. The table 2 fallacy: presenting and interpreting confounder and modifier coefficients. Am J Epidemiol. 2013;177:292-8.
Jardine M, Bourassa C, Piyesis MK. Digging deep: barriers to HIV care among Indigenous women. Turtle Island J Indig Health. 2021;1(2):60-70.
Australian Bureau of Statistics. Births, Australia: statistics about births and fertility rates for Australia, states and territories and sub-state regions. 2021 Available from: https://www.abs.gov.au/statistics/people/population/births-australia/latest-release#data-download
Madden A, Hopwood M, Neale J, Treloar C. Beyond interferon side effects: what residual barriers exist to DAA hepatitis C treatment for people who inject drugs? PLoS One. 2018;13:e0207226.
Taye BW, Valery PC, Liddle B, Woodward AJ, Sackey D, Williams S, et al. Fitting health care to people: understanding and adapting to the epidemiology and health literacy of people affected by viral hepatitis from culturally and linguistically diverse migrant backgrounds. J Immigr Minor Health. 2022;24:1196-205.
De Monte A, Courjon J, Anty R, Cua E, Naqvi A, Mondain V, et al. Direct-acting antiviral treatment in adults infected with hepatitis C virus: reactivation of hepatitis B virus coinfection as a further challenge. J Clin Virol. 2016;78:27-30.
Australian Bureau of Statistics. Prisoners in Australia 2021. Canberra: Australian Bureau of Statistics; 2021 Available from: https://www.abs.gov.au/statistics/people/crime-and-justice/prisoners-australia/latest-release
Yee J, Carson JM, Hajarizadeh B, Hanson J, O'Beirne J, Iser D, et al. High effectiveness of broad access direct-acting antiviral therapy for hepatitis C in an Australian real-world cohort: the REACH-C study. Hepatol Commun. 2022;6:496-512.
Kirby Institute. HIV, viral hepatitis and sexually transmissible infections in Australia: annual surveillance report 2018. Sydney: Kirby Institute, UNSW Sydney; 2018.
Larney S, Hickman M, Guy R, Grebely J, Dore GJ, Gray RT, et al. Estimating the number of people who inject drugs in Australia. BMC Public Health. 2017;17:757.